1. Resistin predicts disease severity and survival in patients with pulmonary arterial hypertension
- Author
-
Li Gao, John Skinner, Tanmay Nath, Qing Lin, Megan Griffiths, Rachel L. Damico, Michael W. Pauciulo, William C. Nichols, Paul M. Hassoun, Allen D. Everett, and Roger A. Johns
- Subjects
Biomarker ,Pulmonary arterial hypertension ,Single nucleotide polymorphism ,SNP ,Machine learning ,Resistin ,Diseases of the respiratory system ,RC705-779 - Abstract
Abstract Background Abnormal remodeling of distal pulmonary arteries in patients with pulmonary arterial hypertension (PAH) leads to progressively increased pulmonary vascular resistance, followed by right ventricular hypertrophy and failure. Despite considerable advancements in PAH treatment prognosis remains poor. We aim to evaluate the potential for using the cytokine resistin as a genetic and biological marker for disease severity and survival in a large cohort of patients with PAH. Methods Biospecimens, clinical, and genetic data for 1121 adults with PAH, including 808 with idiopathic PAH (IPAH) and 313 with scleroderma-associated PAH (SSc-PAH), were obtained from a national repository. Serum resistin levels were measured by ELISA, and associations between resistin levels, clinical variables, and single nucleotide polymorphism genotypes were examined with multivariable regression models. Machine-learning (ML) algorithms were applied to develop and compare risk models for mortality prediction. Results Resistin levels were significantly higher in all PAH samples and PAH subtype (IPAH and SSc-PAH) samples than in controls (P
- Published
- 2024
- Full Text
- View/download PDF